CSF-ctDNA was detected in 59% of cases and showed high concordance (84%) with tumor mutations. Lower variant allelic frequency in CSF-ctDNA was associated with significantly worse survival outcomes.
Impact of Broadening Trial Eligibility Criteria on the Inclusion of Patients With Brain Metastases in Cancer Clinical Trials: Time Series Analyses for 2012-2022 Effective diagnosis, prognostication, ...
Patients with NSCLC who had CSF collection as part of routine clinical care for suspected LMD were included in the study. CSF was evaluated for CTCs and cfDNA using a commercial assay (CNSide; Biocept ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results